手动标记引导与数字引导系统辅助撕囊在超声乳化术中的非劣效随机临床试验
该非劣效随机临床试验纳入156例年龄相关性白内障患者,比较手动标记辅助撕囊(MMAC)与数字引导辅助撕囊(DGAC)的撕囊准确性。结果显示,MMAC组撕囊直径与目标直径的中位偏差在水平和垂直方向均非劣效于DGAC组,理想撕囊比例两组差异亦在非劣效界值内。作者认为MMAC无需特殊设备,若其他中心获得相似结果,可考虑常规用于临床。
要点
- MMAC组撕囊直径水平偏差中位0.22 mm,DGAC组0.27 mm,差异-0.05 mm(95%CI -0.16至0.07),在0.20 mm非劣效界值内。
- MMAC组理想撕囊比例为96.2%(75/78),DGAC组为88.5%(69/78),差异7.7%(95%CI -0.6至16.0),在-5.0%非劣效界值内。
- 作者认为MMAC无需特殊设备,若其他中心获得相似结果,可考虑常规用于临床。
核心结论
- 本试验结果表明,MMAC的撕囊准确性非劣效于DGAC。
- 由于MMAC技术不需要特殊设备,若在其他地方获得相似结果,可考虑将其常规用于临床实践。
研究设计与样本
- 非劣效随机临床试验,于2021年7月至2021年12月在中国中山眼科中心开展,随访至术后1个月。
- 筛查204名成人,纳入156例年龄55至80岁、散瞳后瞳孔直径≥6.5 mm且晶状体混浊分类系统III核混浊度3.0至4.0级的年龄相关性白内障患者。
- 排除既往眼内手术史或可能影响晶状体悬韧带功能的眼病患者;数据分析时间为2024年9月至12月。
主要发现
- MMAC组(平均[SD]年龄71[7]岁;女性47例[60%])与DGAC组(平均[SD]年龄72[7]岁;女性47例[60%])各78例。
- 水平方向撕囊直径与目标直径中位偏差:MMAC组0.22 mm(95%CI 0.11-0.37) vs DGAC组0.27 mm(95%CI 0.14-0.52),差异-0.05 mm(95%CI -0.16至0.07)。
- 垂直方向中位偏差:MMAC组0.27 mm(95%CI 0.12-0.40) vs DGAC组0.33 mm(95%CI 0.20-0.51),差异-0.06 mm(95%CI -0.17至0.05),两者均在0.20 mm非劣效界值内。
- 理想撕囊比例:MMAC组96.2%(75/78) vs DGAC组88.5%(69/78),差异7.7%(95%CI -0.6至16.0),在-5.0%非劣效界值内。
关键数值与推荐
- 主要结局为撕囊直径与目标直径的中位偏差,非劣效界值为0.2 mm。
- 次要结局包括理想撕囊比例、撕囊-人工晶状体(IOL)重叠等级、撕囊偏心距离、术后最佳矫正视力、IOL倾斜和偏心。
- 理想撕囊比例的非劣效界值为-5.0%。
临床怎么用
- 作者认为,MMAC技术不需要特殊设备,若在其他地方获得相似结果,可考虑将其常规用于临床实践。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Appropriately sized and well-centered capsulorhexis is key for high-quality phacoemulsification cataract surgery and can be achieved with digital-guidance devices. However, such devices are not readily available, warranting the need for a device-free manual auxiliary capsulorhexis technique. OBJECTIVES: To determine if manual marking-assisted capsulorhexis (MMAC) is noninferior to a digital guidance-assisted capsulorhexis (DGAC) in capsulorhexis accuracy following phacoemulsification for age-related cataract. DESIGN, SETTING, AND PARTICIPANTS: This noninferiority randomized clinical trial was conducted between July 2021 and December 2021 at Zhongshan Ophthalmic Center, China, with follow-up through 1 month after surgery. Of 204 adults screened, 156 were included who were aged 55 to 80 years and had pupil diameter ≥6.5 mm after pupil dilation and Lens Opacities Classification System III with nuclear opalescence grade of 3.0 to 4.0. Patients were excluded if they had previous intraocular surgery or a diagnosed eye disease that might affect functions of lens suspensory ligament. Data were analyzed from September to December 2024. INTERVENTIONS: In the MMAC group, a lens caliper was used to measure and locate capsulorhexis position, subsequently applying its blunt head to mark the anterior lens capsule for capsulotomy guidance. In the DGAC group, a ring with predefined target diameter was projected to guide capsulorhexis. MAIN OUTCOMES AND MEASURES: The primary outcome was the median deviation of capsulorhexis diameter from the target diameter with a noninferiority margin of 0.2 mm. Secondary outcomes included ratio of ideal capsulorhexis, grades of capsulorhexis-intraocular lens (IOL) overlap, off-center distance of capsulorhexis, postoperative best-corrected visual acuity, IOL tilt, and decentration. RESULTS: Among 156 participants randomized into the MMAC group (mean [SD] age, 71 [7] years; 47 [60%] female) or DGAC group (mean [SD] age, 72 [7]; 47 [60%] female), median deviations comparing the capsulorhexis and target diameters were 0.22 mm (95% CI, 0.11-0.37) in the MMAC group vs 0.27 mm (95% CI, 0.14-0.52) in the DGAC group (difference, -0.05 mm; 95% CI, -0.16 to 0.07) for horizontal diameter and 0.27 mm (95% CI, 0.12-0.40) vs 0.33 mm (95% CI, 0.20-0.51) (difference, -0.06 mm; 95% CI, -0.17 to 0.05), respectively, for vertical diameters, both within the noninferiority margin of 0.20 mm. The proportion of ideal capsulorhexis was 96.2% (75 of 78) in the MMAC group and 88.5% (69 of 78) in the DGAC group (difference, 7.7%; 95% CI, -0.6 to 16.0), also within the noninferiority margin of -5.0%. CONCLUSIONS AND RELEVANCE: The findings in this trial indicate that accuracy of capsulorhexis with MMAC was noninferior to DGAC. Since the MMAC technique does not require special equipment, it might be considered routinely in clinical practice settings if similar outcomes are obtained elsewhere. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04977115.
引用
- Chen X, Liu Z, Jin L, et al. Manual Marking Guidance vs Digital Guidance System-Assisted Capsulorhexis in Phacoemulsification: A Noninferiority Randomized Clinical Trial. JAMA Ophthalmol. 2026. PMID: 41231447. doi:10.1001/jamaophthalmol.2025.4448
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。